Opdivo (nivolumab) - Articles and news items

N is for Nivolumab

Blog / 1 December 2016 / Niamh Louise Marriott, Digital Editor

N is for Nivolumab – the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research…

SMC ‘U-turn’ offers lifeline to Scottish skin cancer patients

Industry news / 8 August 2016 / Bristol-Myers Squibb

The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access in Scotland on par with the rest of the UK…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+